Targeted Therapy Agent
Phase 2Small molecule
Targeted Therapy Agent is one of 91 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPhase 3
Botensilimab
AAgenus Inc.
Phase 3
TAS 102
Taiho Oncology, Inc.Phase 3
5-Fu
TToray Industries, Inc
Phase 3
Cytokine-Induced Killer Cells
TThe First People's Hospital of Changzhou
Phase 3
SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
IBI363
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Iron Isomaltoside
TThomas Jefferson University
Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer
Unknown status·—·Phase 1·NCT05573373·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Targeted Therapy Agent. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details